Propanc Biopharma announces new preclinical pancreatic cancer data
Propanc Biopharma said PRP preclinical results showed >90% tumor growth inhibition and >2.5-fold survival benefit in pancreatic cancer.
Story updates
12:31:52 PM UTC
SquawkNews
PPCB Propanc Biopharma Announces Compelling New Preclinical Pancreatic Cancer Data for PRP Showing >90% Tumor Growth Inhibition and >2.5-Fold Survival Benefit
12:37:42 PM UTC
SquawkNews
Propanc Biopharma Announces Compelling New Preclinical Pancreatic Cancer Data for PRP Showing >90% Tumor Growth Inhibition and >2.5-Fold Survival Benefit
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.